Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.

[1]  I. Vergote,et al.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Gynecologic oncology.

[2]  H. Kitchener,et al.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.

[3]  U. Menon,et al.  Predictors of complications in gynaecological oncological surgery: a prospective multicentre study (UKGOSOC—UK gynaecological oncology surgical outcomes and complications) , 2014, British Journal of Cancer.

[4]  L. Azevedo,et al.  Outcomes for patients with cancer admitted to the ICU requiring ventilatory support: results from a prospective multicenter study. , 2014, Chest.

[5]  Ameen Abu-Hanna,et al.  Mortality After Hospital Discharge in ICU Patients* , 2013, Critical care medicine.

[6]  J. Lucci,et al.  Malnutrition as a predictor of poor postoperative outcomes in gynecologic cancer patients , 2011, Archives of Gynecology and Obstetrics.

[7]  Lee-lynn Chen,et al.  Predictors of Intensive Care Unit Utilization in Gynecologic Oncology Surgery , 2011, International Journal of Gynecologic Cancer.

[8]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[9]  G. Scambia,et al.  Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. , 2008, American journal of obstetrics and gynecology.

[10]  R. Bristow,et al.  Predictors of extended intensive care unit resource utilization following surgery for ovarian cancer. , 2007, Gynecologic oncology.

[11]  B. Hansen,et al.  Optimal Full Matching and Related Designs via Network Flows , 2006 .

[12]  J. Straughn,et al.  Outcomes of gynecologic oncology patients admitted to the intensive care unit following surgery: a university teaching hospital experience , 2006, International Journal of Gynecologic Cancer.

[13]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Trimble,et al.  Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Laczika,et al.  Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit , 2000, Critical care medicine.

[16]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.

[17]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.